Página 1

Annual Report 2017 OSTEOARTHRITIS FOUNDATION INTERNATIONAL

C/ Tuset 19, 3º-2ª · 08006 · BARCELONA T.: +34 931 594 015 www.oafifoundation.com Version 01. June 2018

Página 2

Annual Report 2017

CONTENT

1. OAFI’S PRESENTATION .............................................................................................................. 3

1.1 Who we are ......................................................................................................................... 3

1.2 Osteoarthritis, a disease that affects all of us .................................................................... 3

2. STRATEGIC ACTIONS .................................................................................................................. 4

2.1 Osteoarthritis International Association ............................................................................. 4

2.2 OA Task Force ..................................................................................................................... 5

3. SOCIAL ACTIVITIES ..................................................................................................................... 7

3.1 I International Congress of OA Patients .............................................................................. 7

3.2 Social Program: “Talking about Joint Health” ..................................................................... 9

3.3 Workshops ........................................................................................................................ 10

3.4 Charitable Activities .......................................................................................................... 10

3.4.1 Free Access to Advise ......................................................................................................... 10

3.4.2 Advisory Board of Patients ................................................................................................. 11

3.4.3 Nordic Walking training course and a race ........................................................................ 11

3.4.4 Charitable snack event ....................................................................................................... 11

4. SCIENTIFIC RESEARCH.............................................................................................................. 12

5. SCIENTIFIC DISSEMINATION .................................................................................................... 14

5.1 Workshop: “Osteoarthritis in the XXI century” ................................................................ 14

5.2 Congresses and Conferences ............................................................................................ 14

6. COMMUNICATION AND AWARENESS ..................................................................................... 16

8. FINANCIAL STATEMENT ................................................................................................... 19

Página 3

1. OAFI’S PRESENTATION

1.1 Who we are The Osteoarthritis Foundation International (OAFI) is an independent non-profit foundation, that was created to prevent, treat and improve the quality of life of people suffering from osteoarthritis (OA) by providing them with the necessary tools to help them manage their disease. OAFI has its headquarters in Barcelona (Spain). For this reason, the foundational activity focuses on the following activities:

• Increase social awareness about OA

• Improve the quality of life of patients and the prevention of risk groups (elderly people, sportspersons, postmenopausal women and children)

• Promote research in osteoarthritis and improve treatment For us, patients are the most important.

1.2 Osteoarthritis, a disease that affects all of us OA is a degenerative joint disease that affects the cartilage, bone and soft tissues of the joint. It produces pain and limits us when it comes to doing our daily tasks. It already affects 300 million people in the world according to the Lancet1. Despite its enormous social impact, OA remains an unknown and distant disease for the majority of the population that it is exclusively associated with elderly people. However, it affects very fragmented groups of the population (elderly people, sportspersons, postmenopausal women and children) who have very different needs and who cannot find an answer beyond a general approach.

1 The Lancet is a British medical journal, published weekly by the Lancet Publishing Group, which ranked second in

impact factor in 2016 which measures the frequency with which the average article in a journal has been cited in a particular year.

Página 4

2. STRATEGIC ACTIONS

2.1 Osteoarthritis International Association OAFI promotes the prevention, treatment, and improvement in the quality of life of OA patients by integrating all the agents involved in this pathology, including patients’ associations, medical societies, research centers, public administrations, and collaborating companies to work together against this chronic disease. At present, OAFI has signed agreements with different entities to collaborate in raising awareness of OA in the field of prevention and treatment of this disease.

OAFI leads this cluster of knowledge participated by interdisciplinary entities that work on the improvement of OA patients’ quality of life. In 2017, there were 23 entities working and collaborating together. The main role of each group:

- Patient associations. Members work together in the dissemination and awareness of OA in the society. Participants: Arthritis Foundation (USA), Pan-American League of Rheumatology Associations - PANLAR (representing the American continent), Fondation Arthrose (Belgium), Spanish League of Rheumatology (Spain), General Patients Association (Spain) and Spanish Association of Osteoporosis and Osteoarthritis (Spain).

Página 5

- Medical Societies. It integrates relevant Spanish medical societies that have an important role in the care of patients with osteoarthritis, such as the Spanish Society of Rheumatology, Spanish Society of General and Family Doctors, Spanish Society of Primary Care Physicians and the Spanish Society of Traumatology in Sport.

- Research centers. Teófilo Hernando Foundation, Eurecat, Poal Institute of Rheumatology, University of Barcelona, CEMTRO Clinic, DKF Clinic and WSF promote, in collaboration with OAFI, OA research initiatives in the field of medicine, sports medicine and nutraceuticals.

- Environment. FC Barcelona, Obra Social "la Caixa" and Caminoterapia give us support in the promotion of healthy joints and without pain.

- Collaborating companies. These are companies (Ferrer, OPKO Health, Vanir and AS&NL) that are committed to our foundational activities and actively collaborate with the foundation in the scientific field.

2.2 OA Task Force OAFI co-leads, together with the Arthritis Foundation, the OA Task Force initiative which is an alliance between the most important associations of patients with rheumatologic problems in order to work together globally with a focus on osteoarthritis. Members: Chairman Xavier Carné, Clinic Hospital of Barcelona / European Clinic Research Infrastructures Network (ECRIN), Spain Entities Ann Palmer, Arthritis Foundation, USA Guy Eakin, Arthritis Foundation, USA Josep Vergés, Osteoarthritis Foundation International (OAFI), Spain Carlo V. Caballero-Uribe, Pan-American League of Rheumatology Associations (PANLAR), Colombia Maritza Quintero, Pan-American League of Rheumatology Associations (PANLAR), Venezuela Yves Henrotin, Osteoarthritis Foundation (Belgium) Experts Jordi Monfort, Hospital del Mar, Spain Marco Matucci, Italian Rheumatology Association / Scleroderma Foundation, Italy Ingrid Möller, Institut Poal de Reumatologia, Spain Francisco de Abajo, Alcalá de Henares University - Medical School, Spain Patrick du Souich, Montréal University - Medical School, Canada Virginia Kraus, Duke University - Medical School, USA Montserrat Romera-Baurés, Spanish Rheumatology Society (SER)

Página 6

OA Task Force members are currently working together in the following projects: Quality of Life (QoL) Systematic Literature Review. The purpose of the OA QoL systematic literature review is to provide a “state of the science” review of the international knowledge base on QoL in knee OA patients. During 2017, we reviewed 9,143 international publications. Global Osteoarthritis (OA) Patient Perception Survey. International Survey to develop a multilingual Global OA Patient Perception Survey and implementation strategy that will provide medical professionals, researchers, patients, and policymakers with data on OA patient perceptions at the country, regional, and global levels. This survey, which has already been prepared and validated in the languages of participating countries, will be carried out in Spain, Italy, the US, Mexico, Argentina, Colombia and Venezuela. During the elaboration of the survey, it was key the accuracy of translations in different languages (English, Spanish and Italian) to ensure respondents would receive and understand the same information. In addition, the questionnaire format was addressed for its implementation in each of the countries. The data and privacy management were also handled according to the regulations of each participating country. Finally, the annual meeting was held on October 9, 2017 to follow up the project progression, determine the next steps and design the schedule of activities.

Página 7

3. SOCIAL ACTIVITIES

3.1 I International Congress of OA Patients

OAFI organized, with the collaboration of Obra Social "la Caixa", it first international congress that took place on the 9th and 10th October 2017 at the CosmoCaixa (Barcelona). The purpose of such annual public event is to provide a forum for the exchange of awareness and social knowledge aimed at patients with osteoarthritis and risk groups (elderly, sportsmen and postmenopausal women) to improve their quality of life. Results and the impact of both, press and television, were successful. Watch video: https://www.youtube.com/watch?v=sQDfwFHoqc0

The program included social activities, roundtables and conferences to discuss on OA, its socioeconomic impact and how OA poses a threat for our society and the Health care System. Lecturers presented the prevalence of OA in women, the relationship between doctor-patient, the role of the patient in R&D and in the regulatory issues and how important is doing exercise and go on a healthy diet. Picture of Tai Chi Session

PROGRAMA:

Monday October 9th – Auditorium

10:00 Welcome

Ms. Paloma Casado, Ministry of Health, Social Services and Equality

Representative Department of Health, Generalitat de Catalunya

Ms. Cristina Segura, Director of Social Area Department at Fundación Bancaria La Caixa

Dr. Josep Vergés, President & CEO at OAFI Foundation

10:15 Osteoarthritis, a challenge for the future

Dr. Josep Vergés, President & CEO at OAFI Foundation

10:45 OA Patient’s perception and quality of life

Ms. Ann Palmer, President & y CEO at Arthritis Foundation

Mr. Dieter Wiek, Vice-president at PARE – European League Against Rheumatism

Dr. Josep Vergés, President & CEO at OAFI Foundation

Página 8

Dr. Maritza Quintero, vice-coordinator of OA group of PANLAR, Pan-American League of Rheumatology Associations (PANLAR)

Mr. Benito Martos, President at Spanish League of Rheumatology (Spain)

12:00 Tai-Chi workshop for all ages

Mr. Mark Ricart, Tai-chi teacher

Mrs. Conxita Hernández, Tai-chi teacher

Mrs. Montserrat Servalós, Espai SHEN, Barcelona

13:00 Lunch

14:30 Women and OA. Roundtable of women's health specialists

Dr. Ingrid Möller, Instituto POAL, Barcelona

Dr. Montse Romera, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat

Ms. Maria Josep Sans, Patient and volunteer at the OAFI Foundation

Ms. Montse Mechó, Parachutist and volunteer at the OAFI Foundation

Tuesday October 10th 2017 - Auditorium

09:00 Informed patient vs. Empowered patient

Dr. Jordi Monfort, Hospital del Mar, Barcelona

10:00 Multiple joint osteoarthritis. Each joint, a different disease

Dr. Oswaldo Castañeda, Clínica Angloamericana, Lima, Perú

10:30 Patients in the R+D+i and in the drugs’ regulation

Dr. Fernando García Alonso, Scientific manager, Ferrer

Mr. Julio Sánchez Fierro, Vice-president at Spanish Association of Health Law

Mr. Enric Banda, Barcelona Supercomputing Center

Dr. Xavier Carné, President of the Ethics committee in Clinical Research at Hospital Clínic, Barcelona

11:30 Physician and empowered patient relationship in the XXI century

Dr. Antonio García, President Instituto at Teófilo Hernando

Dr. José Luis Llisterri, President at Spanish Society of General and Family Doctors

Dr. Jose Vicente Moreno, Honorary president at Spanish Society of Rheumatology

Dr. Jordi Ardèvol, President at the Scientific Committee, Spanish Society of Traumatology in Sport.

12:30 Nordic Walking Initiation

Dr. Ramón López, Caminoterapia foundation

Mr. Antonio Brieba, Walkim

13:30 Lunch

14:30 Why is osteoarthritis a non-glamorous disease? Osteoarthritis in

Media

Mr. Ricardo Aparicio, Journalist at Vivir mejor, Health supplement (La Vanguardia)

Dr. Josep Vergés, President & CEO at OAFI Foundation

15:30 Osteoarthritis and sport

What is Barça Innovation Hub?

Ms. Marta Aubia, Head of Barça Innovation Hub, FC Barcelona

Página 9

Dr. Gil Rodas, Medical Services, FC Barcelona

Roundtable on sports medicine

Dr. José María Villalón, Atlético de Madrid medical services

Dr. Gil Rodas, Medical Services at FC Barcelona

Mr. Jesús García Bragado, Olympic athlete

Mr. Manel González, Olympic athlete

16:30 Closing

Ms. Neus Rams, Department of Health, Generalitat de Catalunya

Dr. Josep Vergés, President & CEO at OAFI Foundation

3.2 Social Program: “Talking about Joint Health” This is a collaborative project between the Obra Social "la Caixa" and the Osteoarthritis Foundation International (OAFI). “Talking about OA” program aims to provide elderly people from senior centers of the “La Caixa” with tools to help them manage their joint problems so that they can improve their quality of life by using non-pharmacological measures.

Workshops took place in 20 centers previously selected from “La Caixa”. The first three workshops were done at the end of 2016 and the rest in 2017.

Participating Senior centers:

Bruc, Esplai Bellvitge – L’Hospitalet de Llobregat, Esplai Bonanova - BCN, Esplai Calella, Esplai Reus, Esplai Sant Lluís - BCN, Esplai Vilanova i la Geltrú, Esplai Sagrada Família - BCN, EspaiCaixa Viladecans, Esplai Amposta, Esplai

La Seu d'Urgell, Esplai Sanllehí - Barcelona, Esplai Balàfia - Lleida, Esplai La Bisbal, Esplai Granollers, Esplai Sabadell, Esplai Mollet del Vallés, Esplai Caldes de Malavella, Esplai Espai Caixa Girona Santa Coloma de Gramenet, Esplai

In each center, a visual presentation was made to underpin the message. At the end of each session, questionnaires of assessment and quality of the workshop were distributed. Results obtained are as it follows:

- Attendance: + 1,200 people in 20 sessions. - There were collected 780 questionnaires to get the opinion of attendees. - 65% reported having regular joint pain. - 84% expressed interest in deepening more on joint health issues. - Workshops were highly rated, reporting over 93% as satisfactory or very satisfactory in

the following aspects: o Preparation and knowledge of the topics o Clarity and argumentation o Use of visual tools and others o Workshop methodology

Página 10

- 89% reported that the session allowed them to acquire new knowledge.

Esplai de Sant Lluís Esplai La Seu D’Urgell Esplai de Balàfia (Lleida)

3.3 Workshops A priority of the OAFI is to increase social awareness and run training courses for patients with OA and risk groups in order to stop being OA as an unknown disease which is wrongly associated to ailments that affect mainly people in old age.

CC Can Castelló

In 2017, OAFI participated in several workshops: 1. Osteoarthritis: Prevention, treatment and improvement of the quality, Associació de

Veïns Centre Cívic Jaume Oller, Granollers (Barcelona) 10 March 2017 2. Osteoarthritis: Prevention, treatment, Centre Cívic Pati Llimona, Barcelona, 10 April 2017 3. Osteoarthritis: Prevention, treatment and improvement of the quality, Centre Cívic

Convent de Sant Agustí, Barcelona, 3 May 2017 4. Workshop: “Osteoarthritis in the XXI century”, Spanish Ministry of Health, Madrid, 12 June

2017

5. Osteoarthritis: Prevention, treatment and improvement of the quality, Centre Cívi Sarrià, Barcelona, 11 October 2017

6. Nutrition and Osteoarthritis, Centre Cívic Can Castelló, Barcelona, 18 and 25 October 2017 7. Osteoarthritis: Prevention, treatment and improvement of the quality, Campus UPC Baix

Llobregat, Castelldefels (Barcelona), 28 November 2017

3.4 Charitable Activities 3.4.1 Free Access to Advise OA patients are a priority for OAFI. That is why we offer free access to advising patients, mainly with low income. We listen, give advice and help them. In 2017, OAFI visited 23 patients who urged assistance.

Página 11

3.4.2 Advisory Board of Patients At the end of 2017, OAFI formed its Advisory Board of Patients. The first meeting was participated by 8 volunteers in December. It was agreed to work on the following topics and set an action plan to: - Increase the number of volunteers - Plan and organize social activities for patients - Increase the visibility of the foundation to reach out to OA patients 3.4.3 Nordic Walking training course and a race On October 29, the Osteoarthritis Foundation International (OAFI), the Caminoterapia Foundation and the Walkim company organized a Nordic Walking training course and a race at the Can Dragó Municipal Sports Center in Barcelona, in collaboration with the Eurofitness - sports club. The event was aimed at both osteoarthritis patients and people who wanted to take care of their joint health. Several studies point out the benefits of Nordic Walking for joints and muscles. 3.4.4 Charitable snack event

On December 14, OAFI organized a Charitable event to celebrate Christmas with a snack. The objective was to gather volunteers and friends of the OAFI to share with them a snack and a glass of cava. There were surprises such as live music and the raffle of gifts. People made a donation when having access.

Página 12

4. SCIENTIFIC RESEARCH

Clinical Trials - Clinical trial for a new treatment of knee osteoarthritis in the general

population…………………. in progress OAFI is co-promoter of the study to provide advice and for the benefit of the patient. OAFI provides the following activities to:

• Support to the STUDY and Protocol design • Supervision and advice in the coordination of the STUDY • Support in the selection of hospitals for the development of the STUDY • Propose the PRINCIPAL RESEARCHER and the rest of the researchers. • Organize meetings with the Ethics Committees (CEICs), medical societies and, if

necessary, with the Spanish Agency of Drugs and Health Products to provide the patients perspective

Regulatory - Appropriate Use of Chondroitin Sulphate (CS), Glucosamine (G), or its combination (CS+G)

for the treatment of OA Patients…………………. in progress There are several treatments (physical therapy, analgesia, drugs, surgery ...) in the management of osteoarthritis. In regard to oral treatments, these ones include Chondroitin Sulphate (CS), Glucosamine (G), or its combination (CS+G). In recent years, the Cochrane has published several articles and systematic literature reviews reporting the efficacy and safety of CS and G compared to other treatments and placebo. However, the treatment of osteoarthritis with CS, G, or CS / G is still controversial. Some guidelines recommend the use of these drugs (CS, G, or CS / G) for some type of patients and others do not do it.

This lack of consensus in the guidelines, together with the controversy among practitioners may lead to the fact that patients with osteoarthritis who could benefit from treatment with CS, G, or CS / G are not receiving it, despite the fact that they could reduce pain and the progression of the disease with fewer adverse effects than other commonly used drugs. Consequently, it is convenient to develop criteria for the appropriate use of CS, G, and CS / G by conducting a DELPHI Study in which experts can discuss, reach consensus and provide recommendations.

Thanks to grants received, this study has been possible to be undertaken. At the end of 2017, OAFI worked on the definition of the foundations of this study and systematic literature review.

Página 13

Patients - Focus group to adjust the Protocol of a Clinical Trial …………………. Finalized One of the critical aspects during the implementation of a Clinical Trial is the phase of patient recruitment. For this reason, a pharmaceutical company aimed to validate its protocol by collecting and analyzing the views of the participating OA patients. OAFI selected 10 individuals, based on criteria previously defined by the company, who were invited to participate in this focus group study.

Página 14

5. SCIENTIFIC DISSEMINATION

5.1 Workshop: “Osteoarthritis in the XXI century” On June 12, 2017, OAFI organized the workshop:"Osteoarthritis in the XXI century" at the Spanish Ministry of Health. The event, attended by around 120 people, was participated by representatives of patient associations, medical societies, health authorities and other personalities. This event was relevant in order to give greater visibility to osteoarthritis and stress the need for working out a plan to deal with this chronic disease.

Dr. Josep Vergés Dr. Carlos Lens y Dr.Josep Vergés Presidentes SEMERGEN, SER, SETRADE, SEMG Galicia

Agenda:

5.2 Congresses and Conferences OAFI is concerned about the need of being involved in scientific dissemination in the field of OA. For this reason, OAFI participated in the following events: 1. Osteoarthritis: A different perspective, Orthopaedics Conference Arab Health 2017,

Dubai, 2 February 2017

2. Osteoarthritis: a social health problem, Hospital Clínic, Barcelona, 17 February 2017

Página 15

3. Joint Health: Medical treatments, INFARMA, Barcelona, 22 March de 2017 4. Master in Monitoring and Management of Clinical Trials: Osteoarthritis: a social health

problem. Diagnoses, physiopathology and treatment. Clinical Case. Universidad Autónoma de Madrid, Madrid, 27 de April de 2017

5. Behavior change to improve from OA, Jornada LIRE17, Madrid, 9 May 2017 6. Poster presentation: Empowering Patients with Osteoarthritis with Non-Pharmacological

Measures, EULAR 2017, Madrid, 14-17 June 2017 7. National Symposium of Patients with Rheumatoid Arthritis, Bogotá (Colombia), 2

September 2017 8. I International Congress of OA Patients, CosmoCaixa, Barcelona, 9-10 October 2017 9. Pharmacoeconomics of osteoarthritis (OA expenditure). Measures of economic savings in

osteoarthritis: the role of the patient, Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, 27 November 2017

Simposium (Colombia) EULAR 2017 INFARMA

Página 16

6. COMMUNICATION AND AWARENESS

OAFI has been very active in 2017 and the foundation carried out many dissemination activities:

1. 16 press releases have been sent (9 institutional, 2 Scientific, 5 Scientific and social activities) that have generated more than 200 impacts on media.

2. More than 200 impacts have been obtained in the media: o Television: 6 o Written press: 18 o Online: 175 o Radio: 1

3. Participation in the relevant Spanish congresses (SER, SEMERGEN, SEMG, SETRADE) 4. Presentation of a poster in the PARE section at the EULAR Congress in Madrid 5. More than 50 articles have been published on the website 6. 35 videos have been uploaded to our YouTube channel 7. A community of more than 6,000 digital users has been created through social

networks In addition, OAFI presented the project “Art Norwalking” program, which was finalist in the fifth edition of the INDESCAT Business and Sports Awards in the category of partnership. This collaborative program between the OAFI and the Caminoterapia Foundation to promote the benefits of Nordic walking for OA patients and risk groups. This initiative is addressed to companies concerned about their employees.

Página 17

OAFI in the media:

Página 18

Página 19

8. FINANCIAL STATEMENT

BALANCE SHEET (IN EUROS)

ASSETS 2017 2016

A) NON-CURRENT ASSETS 353.519,09 51.162,84

I. Intangible assets 12.288,92 0,00

II. Intangible fixed assets 34.160,93 38.362,84

III. Property, Plant and Equipment 0,00 0,00

IV. Historic Heritage Goods 0,00 0,00

V. Long-term investments in companies and entities of the group and associates 0,00 0,00

VI. Long-term financial investments 6.059,17 5.300,00

VII. Deferred tax assets 0,00 0,00

B) CURRENT ASSETS 104.854,58 300.123,44

I. Stocks 0,00 0,00

II. Users, Sponsors and debtors of activities and other accounts receivable 8,89 22.360,21

1. Users and debtors from sales and provision of services 0,00 13.500,00

2. Debtors, entities of the group and associates and other related parties 0,00 0,00

3. Sponsors 0,00 0,00

4. Other debtors 0,00 0,00

5. Staff 0,00 0,00

6. Assets for current tax and other credits with public administrations 8,89 8.860,21

7. Founders and partners for pending disbursements 0,00 0,00

III. Investments in short-term companies and group entities and associates 0,00 0,00

IV. Short-term financial investments 0,00 0,00

V. Short-term accruals 377,31 0,00

VII. Cash and other equivalent liquid assets 104.468,38 277.763,23

TOTAL ASSETS (A + B) 458.373,67 351.286,28

BALANCE SHEET (IN EUROS)

LIABILITIES 2017 2016

A) SHAREHOLDERS' EQUITY 125.944,22 300.508,81

A1) Capital Stock 125.944,22 300.508,81

I. Endowment funds or social funds 301.010,07 7.500,00

1. Endowment funds or social funds 323.510,07 30.000,00

2. Endowment funds or social funds pending disbursement -22.500,00 -22.500,00

II. Special funds -501,26 -501,26

III. Retained earnings from previous years 0,00 0,00

IV. Surpluses pending application in statutory activities 0,00 0,00

Página 20

V. Retained earnings from last year -

174.564,59 293.510,07

VI. Contributions to compensate losses 0,00 0,00

A-2) Subsidies, donations and bequests received and other adjustments 0,00 0,00

1. Official capital subsidies 0,00 0,00

2. Capital donations and bequests 0,00 0,00

3. Other grants, donations and bequests 0,00 0,00

4. Fiscal revenues to be distributed 0,00 0,00

B) NON-CURRENT LIABILITIES 0,00 0,00

I. Long-term provisions 0,00 0,00

II. Long term debts 0,00 0,00

1. Debts with credit institutions 0,00 0,00

2. Other long-term debts 0,00 0,00

III. Long-term debts with entities of the group and associates 0,00 0,00

IV. Deferred tax liability 0,00 0,00

V. Long-term accruals 0,00 0,00

C) CURRENT LIABILITIES 31.419,38 43.277,47

I. Short-term provisions 0,00 0,00

II. Short term debts 2.585,31 4.849,47

III. Short-term debts with entities of the group and associates 0,00 0,00

IV. Creditors for activities and other accounts payable 28.834,07 38.428,00

1. Suppliers 0,00 0,00

2. Creditors 4.045,68 984,20

3. Staff (salaries pending payment) 0,00 0,00

4. Liabilities for current taxes and other debts with public administrations 24.788,39 37.443,80

5. Down payments of users 0,00 0,00

VII. Short-term accruals 0,00 0,00

TOTAL LIABILITIES (A + B + C) 157.363,60 343.786,28

Página 21

INCOME STATEMENT (IN EUROS) 2017 2016

1. Ordinary income 370.206,90 460.330,58

a) Sales and provision of services 280.206,90 35330,58

b) Income received on a regular basis 0,00 0,00

c) Income from promotions, sponsors and collaborations 23.000,00 0,00

d) Subsidies, donations and bequests received in the fiscal year 67.000,00 425.000,00

2. Subsidies granted and other expenses -2.083,33 0,00

a) Subsidies granted -2.083,33 0,00

b) Expenses for collaborations and for acting as member of the board of directors 0,00 0,00

3. Variation in stocks of finished and semi-finished goods 0,00 0,00

4. Work carried out by the entity for its assets 0,00 0,00

5. Supplies 0,00 0,00

6. Other operating income 450,00 694,57

a) Income from lease 0,00 0,00

b) Other income from accessories and other current activities 450,00 694,57

7. Wage and Salary expenses -362.984,14 -103.647,32

8. Other Operating Expenses -169.697,08 -63.839,76

a) External Services -169.440,88 -63.839,76

a1) Research and development 0,00 0,00

a2) Lease and fees -20.262,54 -6.800,00

a3) Repairs and maintenance -2.329,03 -1.092,09

a4) Independent professional services -77.637,44 -30.215,50

a5) Transport 0,00 0,00

a6) Insurance premium -393,47 -393,24

a7) Banking services -446,34 -107,51

a8) Advertising, promotion and public relations -11.703,10 -846,25

a9) Supplies -2.021,64 -110,92

a10) Other services -54.647,32 -24.274,25

b) Taxes -256,20 0,00

c) Losses, impairment and variation of provisions for operations of the activities 0,00 0,00

d) Other operating expenses 0,00 0,00

9. Depreciation expense -11.240,82 -1.724,78

10. Subsidies, donations and bequests transferred to income in the fiscal year 0,00 0,00

11. Surplus provisions 0,00 0,00

12. Deterioration and result due to alienation of fixed assets 0,00 0,00

13. Other results 0,00 0,00

Página 22

I) GROSS OPERATING PROFIT (1+2+3+4+5+6+7+8+9+10+11+12+13) -175.348,47 291.813,29

14. Interest revenue 58,75 46,78

15. Interest expense -4,21 -100,00

16. Reasonable value variation on financial instruments 0,00 0,00

17. Exchange rate differences 0,17 0,00

18. Deterioration and result due to alienation of financial instruments 0,00 0,00

II) FINANCIAL RESULT (14+15+16+17+18) 54,71 -53,22

III) INCOME BEFORE TAXES (I+II) -175.293,76 291.760,07

19. Income tax 729,17 1.750,00

IV. NET PROFIT (III + 19) -174.564,59 293.510,07

Página 23

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Total

Pending

disbursement

A. BALANCE, END OF YEAR N-2 0,00

I. Adjustments for changes in criteria N-2 and earlier 0,00

II. Adjustments for errors N-2 and earlier 0,00

B. ADJUSTED BALANCE, START OF YEAR N-1 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00

I. Adjustments for changes in criteria N-2 and earlier 0,00

II. Total income and expenses recognized in the equity 0,00

III. Operations in equity 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00

1. Increase in endowment funds / social funds / special funds 0,00

2. (-) Reduction on endowment funds / social funds / special funds 0,00

3. Conversion of financial liabilities into equity (debts redemption) 0,00

4. Other contributions 0,00

IV. Other changes in equity 30.000,00 -23.001,26 0,00

C. BALANCE, END OF YEAR N-1 30.000,00 -23.001,26 0,00 0,00 293.510,07 0,00 0,00 300.508,81

I. Adjustments for criteria changes N-1 0,00

II. Adjustments for errors N-1 0,00

D. ADJUSTED BALANCE, START OF YEAR N 30.000,00 -23.001,26 0,00 0,00 293.510,07 0,00 0,00 300.508,81

I. Retained earnings from last year -174.564,59 -174.564,59

II. Total income and expenses recognized in the equity 0,00

III. Operations in equity 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00

1. Increase in endowment funds / social funds / special funds 0,00

2. (-) Reduction on endowment funds / social funds / special funds 0,00

3. Conversion of financial liabilities into equity (debts redemption) 0,00

4. Other contributions 0,00

IV. Other changes in equity 0,00

E. FINAL BALANCE OF THE YEAR N 30.000,00 -23.001,26 0,00 0,00 118.945,48 0,00 0,00 125.944,22

TOTAL

Funds

Retained

earnings from

previous years

Retained

earnings from

previous years

for statutory

purposes

Retained

earnings from

last year

Economic

contributions

to

compensate

losses

Subsidies,

donations and

bequests

received